Boston Scientific's EU Stent Expansion and Analyst Upgrades Drive 0.93 Rally as $680M Volume Ranks 165th in Market Activity

On October 8, 2025, Boston Scientific (BSX) closed with a 0.93% increase, trading on a volume of $0.68 billion, ranking 165th in market activity among listed stocks. The stock's performance was driven by renewed focus on its cardiovascular device portfolio following a regulatory update in the EU, which expanded labeling for its next-gen stent system. Analyst activity intensified as three major brokerages upgraded the stock to "market outperform" within a seven-day window, citing improved procedural adoption rates in Q3 earnings calls.

Market participants noted mixed sentiment during the session. A pre-market earnings release from a competing medtech firm triggered cross-sector volatility, temporarily pressuring Boston's shares. However, post-earnings buying interest emerged as institutional investors added 230,000 shares through block trades, according to exchange filings. The stock's volume profile showed a 15% concentration in the $62.50-$63.20 range, indicating accumulation by long-term holders.

To run this back-test properly I need a bit more detail: 1. Exchange / universe – Do you want to rank only U.S. listed stocks (NYSE + NASDAQ), or a different universe? 2. Survivorship & data considerations – Should delisted names be included so the back-test reflects the real-time investable universe each day? 3. Transaction costs – Do you want to include commissions/slippage, or assume friction-less trading? 4. Position sizing – Equal-weight the 500 names each day, or weight by something else (e.g., volume or market-cap)? 5. Benchmark – Would you like the results compared with a benchmark such as the S&P 500? Let me know and I’ll set up the back-test accordingly.